The holier than thou attitude doesn’t do you any favours. Go...

First 31 Last

Share
Profile

Follow
Artvandelay01

2,651 Posts.

407

31/08/20

23:44

Post #: 46971210
Share

Originally posted by mordrax: ↑

@galaxy1 your post has no substance, it's just two sentences of opinion which you're entitled to but opinions without facts carry no weight. Same as SaulStones and @Elvis77, I seriously doubt you understand enough of what you copied to summarise the content. The majority of it is in their latest reports and says nothing material. Half of it talks about the addressable plant meat market... a market which they didn't even start out to address in their prospectus (there is no mention of plant based meat in there). Does that mean nothing to you or did you not read back that far?

In fact, what's really sad about this since I started a thread with facts, there has been two sides, one accusing me of down ramping but do not provide anything other than opinions and accusations, and the other side saying it's a bad broker and it's a bad company, *also* not providing any evidence to backup what they say.

This is sad. I do not actually identify with either side.

I want to generate some insightful and informative discussion but instead all I get is emotional responses.

Is there a place to have impartial, informative discussions on stocks? please pm me.

Expand

The holier than thou attitude doesn’t do you any favours. Go read the main thread here - I’ve provided reasons for my position. I don’t need to reiterate them here.

If you don’t know Everblu you haven’t been in the market long enough. I provided examples of companies they work with - you can do your own DD I’m not here to wipe your bum for you

ROO Price at posting: 4.7¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 31 more messages in this thread...

First 31 Last

Add ROO (ASX) to my watchlist

The holier than thou attitude doesn’t do you any favours. Go...

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News